newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

  • AEON held a scheduled BPD Type 2a meeting with the FDA & is awaiting official meeting minutes.
  • Shareholders approved transactions announced in November, including the Daewoong note exchange & PIPE financing.
  • The Daewoong note exchange closed today, reducing outstanding debt & simplifying the capital structure.
  • AEON expects the second closing of the PIPE financing to occur around January 27, 2026, subject to closing conditions.
  • ABP-450 is a biosimilar to BOTOX® manufactured by Daewoong in an FDA-approved facility.
  • AEON holds exclusive U.S. development & distribution rights for therapeutic indications of ABP-450.